These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38393461)

  • 1. Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study.
    Prost P; Duraes M; Georgescu V; Rebel L; Mercier G; Rathat G
    Ann Surg Oncol; 2024 May; 31(5):3269-3279. PubMed ID: 38393461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
    Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
    Front Oncol; 2022; 12():970918. PubMed ID: 36237308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.
    Bristow RE; Palis BE; Chi DS; Cliby WA
    Gynecol Oncol; 2010 Sep; 118(3):262-7. PubMed ID: 20573392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis.
    Chase DM; Mahajan A; Scott DA; Hawkins N; Kalilani L
    BMC Womens Health; 2024 Mar; 24(1):179. PubMed ID: 38491366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN).
    Lecointre L; Velten M; Lodi M; Saadeh R; Lavoué V; Ouldamer L; Bendifallah S; Koskas M; Bolze PA; Collinet P; Canlorbe G; Touboul C; Huchon C; Coutant C; Faller E; Boisramé T; Gantzer J; Martin D; Baldauf JJ; Akladios C; Ballester M
    Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():64-72. PubMed ID: 31864157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Academic Affiliation and Surgical Volume Predict Survival in Head and Neck Cancer Patients Receiving Surgery.
    Farquhar DR; Masood MM; Lenze NR; Sheth S; Patel SN; Lumley C; Zanation AM; Weissler MC; Olshan AF; Hackman TG
    Laryngoscope; 2021 Feb; 131(2):E479-E488. PubMed ID: 32449832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
    Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
    Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
    Zou RY; Yuan L; Chen M; Yao LQ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
    [No Abstract]   [Full Text] [Related]  

  • 14. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
    So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
    Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
    van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
    Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the surgical approach on survival outcomes in patients undergoing radical hysterectomy for cervical cancer: A real-world multicenter study of a large Chinese cohort from 2006 to 2017.
    Guo C; Tang X; Meng Y; Zhang Y; Zhang X; Guo J; Lei X; Qiu J; Hua K
    Cancer Med; 2020 Aug; 9(16):5908-5921. PubMed ID: 32628356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
    Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
    JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
    Zhu J; Ke G; Bi R; Wu X
    J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.